Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Designing tissue-targeting molecules is crucial for drug efficacy, particularly for central nervous system (CNS) targets.
• Accurately predicting brain penetration is challenging for compounds interacting with efflux transporters like P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) at the blood-brain barrier (BBB).
• High efflux ratios (ER) are known indicators of poor brain tissue penetration.

Purpose of the Study:

• To develop and validate predictive models for brain penetration.
• To evaluate an alternative MDR1-MDCK cell line as a superior predictor of brain penetration compared to previous models.
• To establish correlations between in vitro, rodent, non-human primate (NHP), and human in vivo brain penetration data.

Main Methods:

• Utilizing an MDR1-MDCK cell line for parallel analysis of drug efflux.
• Correlating in vitro experimental data with in vivo data from various preclinical and clinical models.
• Analyzing structural and physicochemical properties alongside in vitro and in vivo parameters.

Main Results:

• The MDR1-MDCK cell line demonstrates potential as a more accurate predictor of brain penetration.
• Established correlations between in vitro findings and in vivo brain penetration across species.
• Integrated analysis of molecular properties and transport data provides a comprehensive understanding of brain penetration.

Conclusions:

• The developed models and cell line offer improved quantitative estimation of brain penetration, addressing a key challenge in drug discovery.
• This work provides a framework for predicting drug access to or exclusion from the CNS.
• The findings support the continued development of targeted therapies by refining brain penetration assessments.